ReviewClinical reviews in allergy & immunology2025
Describing Clinical Characteristics and Treatment Course of Patients with Hereditary Alpha-tryptasemia: A Single-center Study.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with hereditary alpha-tryptasemia (HαT) have been shown not only to be more prone to anaphylaxis but also to more severe reactions. The relationship between hypermobility, gastroparesis, gastroesophageal reflux disease (GERD), postural orthostatic tachycardia syndrome (POTS), and HαT has been variably described in the literature although no causal biochemical or genetic link has been identified. Herein, we sought to describe the clinical presentation, treatment, and co-morbidities of patients diagnosed with HαT within the Penn State Health System. Through a retrospective cross-sectional chart review, we report the clinical and therapeutic characteristics of patients who tested positive for HαT genotypes (2α3β, 3α2β) within Penn State Health. Twenty-six percent of patients within our cohort had co-occurring diagnoses of hypermobility (7, 26.9%), or POTS (7, 26.9%) while more than half of patients had GERD (15, 57.7%). Anaphylaxis was reported among 7 (26.9%) with the average number of anaphylactic episodes per patient prior to HαT identification being less than one. Patients with triplication had higher prevalence of hypermobility and POTS and were more likely to receive treatment with omalizumab or cromolyn. Co-morbid hypermobility, POTS and GERD in patients with flushing, urticaria, or anaphylaxis should warrant further investigation for HαT.
Indexed as
Identifiers
40515774What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.